NasdaqGS:INVAPharmaceuticals
Innoviva Board Shift And New Treatment Launch Create Valuation Question
Innoviva (NasdaqGS:INVA) has appointed former Goldman Sachs partner Josephine Linden to its Board following two director resignations linked to work with Syndeio BioSciences.
The departing directors are expected to focus on Syndeio BioSciences, a company in which Innoviva invests and intends to support.
Innoviva has also highlighted a newly approved gonorrhea treatment that it plans to launch later this year.
For investors watching NasdaqGS:INVA, these board changes arrive alongside an...